A new biologic agent for treatment of systemic lupus erythematosus (SLE) being tested in clinical trials is showing promise as a safe and effective new treatment, particularly in patients with more severe disease or serologically active disease.
Explore this issueAugust 2018
Also by this Author
Recently published results of a study that examined the safety and efficacy of atacicept for SLE showed the biologic agent reduced disease activity and severe flares and was well tolerated.1
“The results reported in this paper provide hope that atacicept may have meaningful benefits for lupus patients,” says lead author, Joan T. Merrill, MD, of the Arthritis & Clinical Immunology Program at the Oklahoma Medical Research Association Oklahoma City. “And [it] seems to be safe and well tolerated when reasonable clinical safety measures are used.”